These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 31154006)

  • 1. A population pharmacokinetic study to accelerate early phase clinical development for a novel drug, teriflunomide sodium, to treat systemic lupus erythematosus.
    Yao X; Wu Y; Jiang J; Chen X; Liu D; Hu P
    Eur J Pharm Sci; 2019 Aug; 136():104942. PubMed ID: 31154006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, Pharmacokinetics, and Pharmacogenetics of Single-Dose Teriflunomide Sodium and Leflunomide in Healthy Chinese Subjects.
    Yao X; Wu Y; Jiang J; Hu P; Liu D; Chen X
    Clin Drug Investig; 2019 Jul; 39(7):643-651. PubMed ID: 31016613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Precision Medicine With Leflunomide: Consideration of the DHODH Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis.
    Wiese MD; Hopkins AM; King C; Wechalekar MD; Lee A; Spargo L; Metcalf R; McWilliams L; Hill C; Cleland LG; Proudman SM
    Arthritis Care Res (Hoboken); 2021 Jul; 73(7):983-989. PubMed ID: 32339392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a population pharmacokinetic model and optimal dosing regimen of leflunomide in Korean population.
    Shin Y; Chae D; Park K
    Eur J Pharm Sci; 2023 May; 184():106402. PubMed ID: 36754259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis.
    Hopkins AM; Wiese MD; Proudman SM; O'Doherty CE; Upton RN; Foster DJ
    Br J Clin Pharmacol; 2016 Jan; 81(1):113-23. PubMed ID: 26331989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical delivery of leflunomide for rheumatoid arthritis treatment: evaluation of local tissue deposition of teriflunomide and its anti-inflammatory effects in an arthritis rat model.
    Bae J; Park JW
    Drug Dev Ind Pharm; 2016; 42(2):254-62. PubMed ID: 26006334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a simple HPLC-MS/MS method to simultaneously determine teriflunomide and its metabolite in human plasma and urine: Application to clinical pharmacokinetic study of teriflunomide sodium and leflunomide.
    Yao X; Liu Y; Song L; Jiang J; Xiao F; Liu D; Hu P
    Biomed Chromatogr; 2019 Mar; 33(3):e4420. PubMed ID: 30362147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients.
    Zheng B; Yu XQ; Greth W; Robbie GJ
    Br J Clin Pharmacol; 2016 May; 81(5):918-28. PubMed ID: 26659791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LC-MS/MS Method for the Quantification of the Leflunomide Metabolite, Teriflunomide, in Human Serum/Plasma.
    Rule GS; Rockwood AL; Johnson-Davis KL
    Methods Mol Biol; 2019; 1872():75-83. PubMed ID: 30350281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases.
    Fragoso YD; Brooks JB
    Expert Rev Clin Pharmacol; 2015 May; 8(3):315-20. PubMed ID: 25712857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of hepatic cytochrome P450 enzymes and sodium/bile acid cotransporter exacerbates leflunomide-induced hepatotoxicity.
    Ma LL; Wu ZT; Wang L; Zhang XF; Wang J; Chen C; Ni X; Lin YF; Cao YY; Luan Y; Pan GY
    Acta Pharmacol Sin; 2016 Mar; 37(3):415-24. PubMed ID: 26806301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Teriflunomide for the treatment of multiple sclerosis.
    Warnke C; Stüve O; Kieseier BC
    Clin Neurol Neurosurg; 2013 Dec; 115 Suppl 1():S90-4. PubMed ID: 24321165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus.
    Narwal R; Roskos LK; Robbie GJ
    Clin Pharmacokinet; 2013 Nov; 52(11):1017-27. PubMed ID: 23754736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Semiphysiologically Based Pharmacokinetic Model of Leflunomide Disposition in Rheumatoid Arthritis Patients.
    Hopkins AM; Wiese MD; Proudman SM; O'Doherty CE; Foster D; Upton RN
    CPT Pharmacometrics Syst Pharmacol; 2015 Jun; 4(6):362-71. PubMed ID: 26225264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study.
    Bergner R; Peters L; Schmitt V; Löffler C
    Clin Rheumatol; 2013 Feb; 32(2):267-70. PubMed ID: 23179005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors "leflunomide" and "teriflunomide" in Covid-19: A narrative review.
    Kaur H; Sarma P; Bhattacharyya A; Sharma S; Chhimpa N; Prajapat M; Prakash A; Kumar S; Singh A; Singh R; Avti P; Thota P; Medhi B
    Eur J Pharmacol; 2021 Sep; 906():174233. PubMed ID: 34111397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic response to leflunomide in combo therapy and monotherapy is associated to serum teriflunomide (A77 1726) levels.
    Fajardo-Robledo NS; Jacobo-Cuevas H; Perez-Guerrero EE; Corona-Sanchez EG; Saldaña-Cruz AM; Romero-Tejeda EM; Rodriguez-Jimenez NA; Totsuka-Sutto SE; Lopez-Roa RI; Ponce-Guarneros JM; Alcaraz-Lopez MF; Cerpa-Cruz S; Muñoz-Valle JF; Cardona-Muñoz EG; Gonzalez-Lopez L; Gamez-Nava JI;
    Sci Rep; 2022 Feb; 12(1):1877. PubMed ID: 35115601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program.
    Yapa SW; Roth D; Gordon D; Struemper H
    Lupus; 2016 Nov; 25(13):1448-1455. PubMed ID: 27072354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis.
    Wiese MD; Rowland A; Polasek TM; Sorich MJ; O'Doherty C
    Expert Opin Drug Metab Toxicol; 2013 Aug; 9(8):1025-35. PubMed ID: 23682862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Teriflunomide (Aubagio®) for the treatment of multiple sclerosis.
    Bar-Or A
    Exp Neurol; 2014 Dec; 262 Pt A():57-65. PubMed ID: 24925677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.